A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease

Transplantation

Volumn 85, Issue 1, 2008, Pages 102-111

  Nestvold, Janne M ^a   Omdal, Bente K ^a   Dai, Ke Zheng ^b   Martens, Anton ^c   Benestad, Haakon B ^a   Vaage, John T ^b   Rolstad, Bent ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acute myeloid leukemia; Chimerism; Donor lymphocyte infusions; Graft versus leukemia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; CHIMERISM; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NEOPLASM, RESIDUAL; RATS; RATS, INBRED BN; RATS, NUDE; T-LYMPHOCYTES;

EID: 38149076071     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000296856.53493.1f     Document Type: Article

References (43)

1. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948.
2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
4. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895.
5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
6. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79.
7. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase ii study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447.
8. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661.
9. Slavin S, Morecki S, Weiss L, et al. Nonmyeloablative stem cell transplantation: Reduced-intensity conditioning for cancer immunotherapy - from bench to patient bedside. Semin Oncol 2004; 31: 4.
10. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus- malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18.
11. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320.
12. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041.
13. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39.
14. Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414.
15. Rolstad B, Naper C, Lovik G, et al. Rat natural killer cell receptor systems and recognition of MHC class I molecules. Immunol Rev 2001; 181: 149.
16. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237.
17. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835.
18. Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261.
19. Engh E, Strom-Gundersen I, Benestad HB, Rolstad B. Long-term donor chimerism after MHC (RT1) mismatched bone marrow transplantation in the rat: The role of host alloreactive NK cells. Scand J Immunol 2001; 54: 198.
20. Martens AC, Johnson RJ, Kaizer H, Hagenbeek A. Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells. Exp Hematol 1984; 12: 667.
21. Perez-Simon JA, Caballero D, Ez-Campelo M et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423.
22. Recommendations for the health monitoring of mouse, rat, hamster, guineapig and rabbit breeding colonies. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management November 1992. Lab Anim 1994; 28: 1.
23. McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia: Development, application and future perspectives. Leukemia 2005; 19: 687.
24. Martens AC, van Bekkum DW, Hagenbeek A. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)). Leukemia 1990; 4: 241.
25. Kampinga J, Kroese FG, Pol GH, et al. RT7-defined alloantigens in rats are part of the leucocyte common antigen family. Scand J Immunol 1990; 31: 699.
26. Leong LYW, Le Rolle AF, Deverson EV, et al. RT1-U: Identification of a novel, active, class Ib alloantigen of the rat MHC. J Immunol 1999; 162: 743.
27. Reisner Y, Gur H, Reich-Zeliger S, et al. Hematopoietic stem cell transplantation across major genetic barriers: Tolerance induction by megadose CD34 cells and other veto cells. Ann NY Acad Sci 2005; 1044: 70.
28. Bachar-Lustig E, Rachamim N, Li HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268.
29. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186.
30. Schulenburg A, Fischer M, Kalhs P, et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leukemia Lymphoma 2005; 46: 1755.
31. Naper C, Vaage JT, Lambracht D, et al. Alloreactive natural killer cells in the rat: complex genetics of MHC control. Eur J Immuol 1995; 25: 1249.
32. Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005; 105: 1828.
33. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234.
34. Meignin V, de Latour RP, Zuber J, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33: 894.
35. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903.
36. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195: 695.
37. Pillai AB, George TI, Dutt S, et al. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007; 178: 6242.
38. Zeng D, Lewis D, Jbakhsh-Jones S, et al. Bone marrow NK1.1- and NK1.1+ T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073.
39. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935.
40. Williams RM, Singer DE, Rodday P, Bennett M. F1 Hybrid resistance to bn rat myelogenous leukemia parallels resistance to transplantation of normal bn bone marrow. Leukemia Res 1980; 4: 261.
41. Løvik G, Vaage JT, Naper C, et al. Recruitment of alloreactive natural killer cells to the rat peritoneum by a transfected cell line secreting rat recombinant interleukin-2. J Immunol Meth 1995; 179: 59.
42. Rolstad B, Benestad HB. Spontaneous alloreactivity of natural killer (NK) and lymphokine- activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis. Immunology 1991; 74: 86.
43. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417.